Tecfidera(®): an approach for repurposing. - Wikidata - wikimedia - TriplyDB

Tecfidera(®): an approach for repurposing.

Tecfidera(®): an approach for repurposing.

http://www.wikidata.org/entity/Q38192708

about

Tecfidera(®): an approach for repurposing.

http://www.wikidata.org/entity/Q38192708

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Tecfidera(®): an approach for repurposing.

@en

type

label

Tecfidera(®): an approach for repurposing.

@en

prefLabel

Tecfidera(®): an approach for repurposing.

@en

P1433

Q38192708-8C1798AC-94AB-4CA9-9ED5-AB5C0AD7213C

P1476

Q38192708-7C177C72-4A88-46A5-BA29-F663F83FA26C

P2093

Q38192708-E510B07D-AF4B-4E45-A278-FB6A80678F50

P2860

Q38192708-00DF9A4D-2960-4F50-B30C-9C9F6A42FA4D

Q38192708-0FF8BEBC-C848-4F1B-A7F2-760BF5936580

Q38192708-1B1A6082-0AE2-4CDC-8602-ECF6587FBE08

Q38192708-3478F4E5-90CD-4079-9625-149BFD0F257F

Q38192708-3AB2D087-6DC1-4B8A-8807-A5B495B797A9

Q38192708-4DE2F9B6-3192-4C07-B409-C9EE23B94641

Q38192708-55AA22F5-0896-47EF-A2DF-36E9B98C3A1F

Q38192708-66DB4E12-6403-419D-8E63-795C84C7896F

Q38192708-67D016F3-165C-4E2A-B6DC-E9A3C095DD32

Q38192708-6E90B80F-64A9-4A3C-A058-97BBB52088E8

P304

Q38192708-72D0D481-13B2-4279-999D-19BBDC6FFD65

P31

Q38192708-B021A176-347B-4506-8C4E-A15970BB9D9D

P356

Q38192708-934553B3-C714-4617-AE26-572B3938A9DE

P433

Q38192708-2B47B4E4-3F6A-4826-9A1D-D668FB2591FC

P478

Q38192708-A87CE8A2-8E3C-442C-BFD1-C8403F00EBF8

P50

Q38192708-C7A90B6C-B327-47F6-87BA-042C5D45912C

P577

Q38192708-925BF9E8-30C9-4C52-957E-A030DFB2D73B

P698

Q38192708-5342B1D5-0C4A-4CB3-9257-0DF6984A96B8

P356

P1433

Pharmaceutical patent analyst

P1476

Tecfidera(®): an approach for repurposing

@en

P2093

Roxanne P Spencer

http://www.w3.org/2001/XMLSchema#string

P2860

Nicotinic acid- and monomethyl fumarate-induced flushing involves GPR109A expressed by keratinocytes and COX-2-dependent prostanoid formation in mice

In vitro pharmacokinetics of anti-psoriatic fumaric acid esters

Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis

Mechanisms of oxidative damage in multiple sclerosis and neurodegenerative diseases: therapeutic modulation via fumaric acid esters

Polymorphs and prodrugs and salts (oh my!): an empirical analysis of "secondary" pharmaceutical patents

Oxidative stress and proinflammatory cytokines contribute to demyelination and axonal damage in a cerebellar culture model of neuroinflammation

Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis.

Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway.

Treatment of psoriasis with fumaric acid esters (Fumaderm).

Fumarates improve psoriasis and multiple sclerosis by inducing type II dendritic cells

P304

183-198

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4155/PPA.14.9

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

3

http://www.w3.org/2001/XMLSchema#string

P50

Roxanne P Spencer

P577

2014-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24588595

http://www.w3.org/2001/XMLSchema#string